{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:44:41Z","timestamp":1775763881576,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515010409"],"award-info":[{"award-number":["2020A1515010409"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["201904010488"],"award-info":[{"award-number":["201904010488"]}],"id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160039"],"award-info":[{"award-number":["82160039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700162"],"award-info":[{"award-number":["81700162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Open project of Yunnan Blood Disease Clinical Medical Center","award":["2020LCZXKF-XY05"],"award-info":[{"award-number":["2020LCZXKF-XY05"]}]},{"name":"the Key Basic Research Project of Guangzhou City-Basic and The Applied Basic Research Program of Science","award":["202201011781"],"award-info":[{"award-number":["202201011781"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40487-023-00255-2","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T17:01:38Z","timestamp":1702746098000},"page":"131-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct05092048","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waiyi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caifeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jixian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanshou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6280-0546","authenticated-orcid":false,"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"issue":"6","key":"255_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/jnci\/djac026","volume":"114","author":"N Keating","year":"2022","unstructured":"Keating N, Brooks G, Landrum M, et al. The oncology care model and adherence to oral cancer drugs: a difference-in-differences analysis. J Natl Cancer Inst. 2022;114(6):871\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"255_CR2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","volume":"36","author":"HE White","year":"2022","unstructured":"White HE, Salmon M, Albano F, et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022;36(7):1834\u201342.","journal-title":"Leukemia"},{"issue":"1","key":"255_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","volume":"7","author":"E Atallah","year":"2021","unstructured":"Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42\u201350.","journal-title":"JAMA Oncol"},{"issue":"8","key":"255_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ajh.26556","volume":"97","author":"E Inzoli","year":"2022","unstructured":"Inzoli E, Aroldi A, Piazza R, Gambacorti-Passerini C. Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success. Am J Hematol. 2022;97(8):1075\u201385.","journal-title":"Am J Hematol"},{"issue":"7","key":"255_CR5","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3324\/haematol.2020.247767","volume":"106","author":"L Janssen","year":"2021","unstructured":"Janssen L, Blijlevens N, Drissen M, et al. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica. 2021;106(7):1876\u201382.","journal-title":"Haematologica"},{"issue":"3","key":"255_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s12325-022-02398-6","volume":"40","author":"M Breccia","year":"2023","unstructured":"Breccia M, Chiodi F, Nardozza A, et al. The economic burden of chronic myeloid leukemia in patients with later lines: findings from a real-world analysis in Italy. Adv Ther. 2023;40(3):961\u201374.","journal-title":"Adv Ther"},{"issue":"8","key":"255_CR7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","volume":"104","author":"C Fava","year":"2019","unstructured":"Fava C, Rege-Cambrin G, Dogliotti I, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104(8):1589\u201396.","journal-title":"Haematologica"},{"issue":"3","key":"255_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ajh.25342","volume":"94","author":"J Cortes","year":"2019","unstructured":"Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346\u201357.","journal-title":"Am J Hematol"},{"issue":"20","key":"255_CR9","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.3390\/cancers13205116","volume":"13","author":"T Ono","year":"2021","unstructured":"Ono T. Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers (Basel). 2021;13(20):5116.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"255_CR10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3390\/cancers12092521","volume":"12","author":"G Etienne","year":"2020","unstructured":"Etienne G, Dulucq S, Bauduer F, et al. Incidences of deep molecular responses and treatment-free remission in de novo CP-CML patients. Cancers (Basel). 2020;12(9):2521.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"255_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357.","journal-title":"Lancet Oncol"},{"issue":"13","key":"255_CR12","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","volume":"4","author":"P Rousselot","year":"2020","unstructured":"Rousselot P, Loiseau C, Delord M, Cayuela J, Spentchian M. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2020;4(13):3034\u201340.","journal-title":"Blood Adv"},{"issue":"4","key":"255_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Aaronson N, et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014;99(4):788\u201393.","journal-title":"Haematologica"},{"issue":"6","key":"255_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.16599","volume":"190","author":"A Turkina","year":"2020","unstructured":"Turkina A, Wang J, Mathews V, et al. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. Br J Haematol. 2020;190(6):869\u201376.","journal-title":"Br J Haematol"},{"issue":"3","key":"255_CR15","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1200\/JOP.2014.001099","volume":"11","author":"SL Goldberg","year":"2015","unstructured":"Goldberg SL, Akard LP, Dugan MJ, Faderl S, Pecora AL. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia. J Oncol Pract. 2015;11(3):e398-404.","journal-title":"J Oncol Pract"},{"issue":"2","key":"255_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00432-021-03624-4","volume":"148","author":"L Yu","year":"2022","unstructured":"Yu L, Wang H, Gale R, et al. Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. J Cancer Res Clin Oncol. 2022;148(2):449\u201359.","journal-title":"J Cancer Res Clin Oncol"},{"key":"255_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/EDBK_201099","volume":"38","author":"T Gilligan","year":"2018","unstructured":"Gilligan T, Salmi L, Enzinger A. Patient\u2013clinician communication is a joint creation: working together toward well-being. Am Soc Clin Oncol Educ Book. 2018;38:532\u2013529.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"255_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","volume":"34","author":"G Sharf","year":"2020","unstructured":"Sharf G, Marin C, Bradley J, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34(8):2102\u201312.","journal-title":"Leukemia"},{"issue":"9","key":"255_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"255_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"issue":"6","key":"255_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1080\/10428194.2018.1535113","volume":"60","author":"GICG Ector","year":"2019","unstructured":"Ector GICG, Govers TM, Westerweel PE, Grutters JPC, Blijlevens NMA. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia. Leuk Lymphoma. 2019;60(6):1485\u201392.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"255_CR22","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3324\/haematol.2021.280377","volume":"107","author":"KE Flynn","year":"2022","unstructured":"Flynn KE, Atallah E, Lin L, et al. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022;107(11):2641\u20139.","journal-title":"Haematologica"},{"key":"255_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35021","author":"F Efficace","year":"2023","unstructured":"Efficace F, Cottone F, Yanez B, et al. Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. Cancer. 2023. https:\/\/doi.org\/10.1002\/cncr.35021.","journal-title":"Cancer"},{"issue":"14","key":"255_CR24","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381\u20138.","journal-title":"J Clin Oncol"},{"key":"255_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106734","volume":"111","author":"M Obeng-Kusi","year":"2021","unstructured":"Obeng-Kusi M, MacDonald K, van Lierde MA, Lee CS, De Geest S, Abraham I. No margin for non-adherence: probabilistic Kaplan\u2013Meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study). Leuk Res. 2021;111: 106734.","journal-title":"Leuk Res"},{"issue":"21","key":"255_CR26","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","volume":"3","author":"C Yamamoto","year":"2019","unstructured":"Yamamoto C, Nakashima H, Ikeda T, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019;3(21):3266\u201377.","journal-title":"Blood Adv"},{"issue":"4","key":"255_CR27","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver R, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"1","key":"255_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/ejh.13524","volume":"106","author":"C Gambacorti-Passerini","year":"2021","unstructured":"Gambacorti-Passerini C, Chen C, Davis C, et al. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. Eur J Haematol. 2021;106(1):82\u20139.","journal-title":"Eur J Haematol"},{"issue":"15","key":"255_CR29","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1002\/cam4.2545","volume":"8","author":"I Abou Dalle","year":"2019","unstructured":"Abou Dalle I, Kantarjian H, Burger J, et al. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019;8(15):6559\u201365.","journal-title":"Cancer Med"},{"issue":"16","key":"255_CR30","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.3390\/cancers13164175","volume":"13","author":"HH Saifullah","year":"2021","unstructured":"Saifullah HH, Lucas CM. Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors? Cancers (Basel). 2021;13(16):4175.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"255_CR31","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.6004\/jnccn.2020.7627","volume":"18","author":"A Garcia-Horton","year":"2020","unstructured":"Garcia-Horton A, Lipton JH. Treatment outcomes in chronic myeloid leukemia: does one size fit all? J Natl Compr Canc Netw. 2020;18(10):1421\u20138.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"255_CR32","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3324\/haematol.2021.280175","volume":"107","author":"G Gugliotta","year":"2022","unstructured":"Gugliotta G, Castagnetti F, Breccia M, et al. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study. Haematologica. 2022;107(10):2356\u201364.","journal-title":"Haematologica"},{"issue":"11","key":"255_CR33","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3390\/jcm9113671","volume":"9","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020;9(11):3671.","journal-title":"J Clin Med"},{"issue":"10","key":"255_CR34","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"M Deininger","year":"2020","unstructured":"Deininger M, Shah N, Altman J, et al. Chronic myeloid leukemia, version 2.2021 NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(10):1385\u2013415.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"255_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709.","journal-title":"Am J Hematol"},{"key":"255_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.679932","volume":"12","author":"M Bao","year":"2021","unstructured":"Bao M, Yang S, Gale RP, et al. Mental health in persons with chronic myeloid leukemia during the SARS-CoV-2 pandemic: the need for increased access to health care services. Front Psychiatry. 2021;12: 679932.","journal-title":"Front Psychiatry"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-023-00255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-023-00255-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-023-00255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:12:34Z","timestamp":1708535554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-023-00255-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1007\/s40487-023-00255-2","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hong Chen, Yan Wen, Yun Zeng, Lie Lin, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Qiang Wang, Xuan Zhou, Xiaoli Liu, Hong Qu, Zhenfang Liu, Xin Du and Na Xu have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was reviewed by the Medical Ethics Committee of Southern Medical University Nanfang Hospital, who confirmed that the research qualified as exempt from medical ethical review under Article 1, \u201cConducting research using legally obtained public data or data generated through observation without interfering with public behavior,\u201d as outlined in the exemption from medical ethics review instructions. Therefore, the application for exemption from medical ethics review for this study was approved. All enrolled patients provided written informed consent before beginning the survey, and the trial was conducted in line with the principles of the Declaration of Helsinki. This study was registered at ClinicalTrials.gov (NCT05092048).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}